2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO, CA
Market cap: $23.9M (2/08/2026)
Price: $0.91
Investor Presentation
Senti Bio Q3 2025 Financial Results and Next Clinical Data for SENTI-202 Study
Earnings Release
Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors
Submission of Matters to a Vote of Security Holders
Senti Bio Receives FDA Orphan Drug Designation for SENTI-202 CAR NK Cell Therapy
Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development
Annual Report to Security Holders
Q3
Q2
Q1
FY 2024
FY 2023 amended
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Initial Statement of Beneficial Ownership